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Abstract
Twenty-seven previously untreated patients with unresectable non-small cell lung cancer were
treated with a 3-drug combination of ifosfamide, cisplatin, and vindesine as a phase II study.
Patients received ifosfamide, 1.3g/m2, on days 1 to 5; cisplatin, 20mg/m2, on days 1 to 5; and
vindesine, 3mg/m2, on days 1 and 8; with a sufficient parenteral hydration. Courses were repeated
every 4 weeks. Twenty males and seven females with a median age of 61 years were treated
and fully evaluated. Five patients had stage IIIA, seven had stage IIIB, and 15 had stage IV
disease. One patient with adenocarcinoma achieved a complete response and 16 achieved a partial
response, for an overall response rate of 63% (95% confidence limit: 45% to 81%). The median
duration of response was 34 weeks (range: 9 to 52 weeks). The median survival time was 58 weeks
for patients with IIIA/B disease, and 33 weeks for those with IV disease. The major toxicity was
myelosuppression, however, it was generally well-tolerated. These results indicate that the 3-drug
combination is active against non-small cell lung cancer and warrants further clinical trials.
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